Terms: = Lymphoma AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4 AND Clinical Outcome
10 results:
1. Senescence-associated reprogramming promotes cancer stemness.
Milanovic M; Fan DNY; Belenki D; Däbritz JHM; Zhao Z; Yu Y; Dörr JR; Dimitrova L; Lenze D; Monteiro Barbosa IA; Mendoza-Parra MA; Kanashova T; Metzner M; Pardon K; Reimann M; Trumpp A; Dörken B; Zuber J; Gronemeyer H; Hummel M; Dittmar G; Lee S; Schmitt CA
Nature; 2018 Jan; 553(7686):96-100. PubMed ID: 29258294
[TBL] [Abstract] [Full Text] [Related]
2. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification.
Van Cutsem E; Bang YJ; Mansoor W; Petty RD; Chao Y; Cunningham D; Ferry DR; Smith NR; Frewer P; Ratnayake J; Stockman PK; Kilgour E; Landers D
Ann Oncol; 2017 Jun; 28(6):1316-1324. PubMed ID: 29177434
[TBL] [Abstract] [Full Text] [Related]
3. Detecting Markers of Therapy-Induced Senescence in Cancer Cells.
Fan DN; Schmitt CA
Methods Mol Biol; 2017; 1534():41-52. PubMed ID: 27812866
[TBL] [Abstract] [Full Text] [Related]
4. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
[TBL] [Abstract] [Full Text] [Related]
5. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract] [Full Text] [Related]
6. EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approaches.
D'Angelo V; Iannotta A; Ramaglia M; Lombardi A; Zarone MR; Desiderio V; Affinita MC; Pecoraro G; Di Martino M; Indolfi P; Casale F; Caraglia M
J Exp Clin Cancer Res; 2015 Aug; 34(1):83. PubMed ID: 26268310
[TBL] [Abstract] [Full Text] [Related]
7. Molecular pathways: deregulation of histone h3 lysine 27 methylation in cancer-different paths, same destination.
Ezponda T; Licht JD
Clin Cancer Res; 2014 Oct; 20(19):5001-8. PubMed ID: 24987060
[TBL] [Abstract] [Full Text] [Related]
8. Epigenetic regulation of microRNAs in acute lymphoblastic leukemia.
Roman-Gomez J; Agirre X; Jiménez-Velasco A; Arqueros V; Vilas-Zornoza A; Rodriguez-Otero P; Martin-Subero I; Garate L; Cordeu L; San José-Eneriz E; Martin V; Castillejo JA; Bandrés E; Calasanz MJ; Siebert R; Heiniger A; Torres A; Prosper F
J Clin Oncol; 2009 Mar; 27(8):1316-22. PubMed ID: 19164206
[TBL] [Abstract] [Full Text] [Related]
9. Monoclonal IgH gene rearrangement in microdissected nodules from nodular sclerosis Hodgkin disease.
Izban KF; Nawrocki JF; Alkan S; Hsi ED
Am J Clin Pathol; 1998 Nov; 110(5):599-606. PubMed ID: 9802344
[TBL] [Abstract] [Full Text] [Related]
10. Immunohistochemical characteristics of Hodgkin and Reed-Sternberg cells in relation to age and clinical outcome.
Enblad G; Sundström C; Glimelius B
Histopathology; 1993 Jun; 22(6):535-41. PubMed ID: 8354486
[TBL] [Abstract] [Full Text] [Related]
